Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.45 HKD | -1.82% | +8.45% | -49.09% |
May. 16 | WuXi AppTec Denies Being a Security Threat to US | MT |
May. 16 | HONG KONG SHARES OF WUXI APPTEC SET TO OPEN DOWN 2.1% AFTER US H… | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-49.09% | 18B | - | ||
+8.98% | 114B | B+ | ||
+11.36% | 104B | B+ | ||
-12.58% | 22.41B | B+ | ||
-1.05% | 22.28B | B | ||
-5.29% | 19.07B | A- | ||
-2.46% | 17.89B | B | ||
+8.11% | 14.28B | C+ | ||
+34.93% | 12.55B | C+ | ||
-24.30% | 8.45B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603259 Stock
- 2359 Stock
- Ratings WuXi AppTec Co., Ltd.